VBIV VBI Vaccines Inc: רווח למניה לשנה מתגלגלת

The scientific drive of the Canadian-Israeli VBI Vaccines Inc. (VBIV) team and ambitious patents are creating market volatility, which the current EPS YoY TTM growth rate on GURU.Markets visualizes through the 7.90 level as a critical benchmark. Stability is ensured by outsourcing production to external partners, while delegating trials to specialized CROs minimizes operational risks, sparing the company from excessive capital expenditures.
vbivaccines.com - פילוחים אנליטיים ומדדי מפתח (VBIV)

VBI Vaccines Inc. (VBIV) has lost its competitiveness due to the initiated bankruptcy proceedings and asset liquidation. Analyzing the 12-month YoY earnings per share (EPS) growth, an investor can observe the net income dynamics over four quarters relative to the previous year. This metric measures the efficiency of capital generation per share, revealing trends of business decline. In the current situation, patent investigations make EPS growth unlikely, and the market currently prices in the asset as terminal.